Rubella vaccine

GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older

Retrieved on: 
Monday, June 6, 2022
Public Policy, Government, FDA, Health, Infectious Diseases, Public Policy, General Health, Mumps, Vaccination, Irritability, Association, Immunodeficiency, Rubella vaccine, Vaccine, Thrombocytopenia, Company, ACIP, US Foods, National Center for Immunization and Respiratory Diseases, Food, Contraindication, Thrombocytopenic purpura, Syringe, Annual report, Anaphylaxis, Symptoms of COVID-19, MMR, Pain, CDC, Senior, Fever, Red, Allergy, FDA, Patient, Disease, Mortality, Risk, Syncope, COVID-19, Green Cross (South Korean company), Febrile seizure, Vaccine-preventable diseases, MD, Clinical trial, Pregnancy, GSK, Rubella, Degenerative disease, Stockholm Environment Institute US Center, Measles, Safety, Swelling, Pharmaceutical industry, Medicine

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PRIORIX (Measles, Mumps and Rubella Vaccine, Live) for active immunisation for the prevention of measles, mumps and rubella (MMR) in individuals 12 months of age and older.

Key Points: 
  • GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PRIORIX (Measles, Mumps and Rubella Vaccine, Live) for active immunisation for the prevention of measles, mumps and rubella (MMR) in individuals 12 months of age and older.
  • PRIORIX may be administered as a first dose, followed by a second dose of PRIORIX.
  • PRIORIX may also be administered as a second dose to individuals who have previously received the first dose of another MMR-containing vaccine.
  • The CDC recommends people get a MMR vaccine to protect against measles, mumps and rubella.

Global Adult Vaccine Industry Trends and Opportunities, 2022-2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 18, 2022
Biotechnology, Pharmaceutical, Health, Measles, GlaxoSmithKline, DPT vaccine, Bacterial pneumonia, Respiratory system, Hepatitis, Man, Cervical cancer, CDC, Government, Prevalence, Influenza, CSL Limited, Fungus, Rubella, Vaccine, Merck & Co., Death, Baloxavir marboxil, HPV, Adult, Degenerative disease, Shingles, Virus, Billion, Center, Respiratory tract, Chickenpox, Pfizer, MMR, Sanofi Pasteur, USD, Rubella vaccine, Centers for Disease Control and Prevention, Thoracic aortic aneurysm, Research, Mumps, BLA, COVID-19, Travel, Vaccination, TAA, CAGR, Pharmaceutical industry, Growth, Neisseria meningitidis, Pneumonia

The "Global Adult Vaccine Market, Size, Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Adult Vaccine Market, Size, Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Recently, the increasing prevalence of diseases and novel vaccine technologies has been significant drivers for the global adult vaccines market.
  • In addition, increased research in vaccine technologies and increasing government support also support the growth of the global adult vaccines market.
  • According to this report Global Adult Vaccine Industry is projected to grow with a CAGR of 6% from 2021-2027.

Micron Biomedical Initiates First-Ever Microneedle Vaccine Clinical Trial in Children

Retrieved on: 
Tuesday, July 13, 2021
Medical specialties, Virology, Vaccines, Microneedle, Medicine, Vaccine, Clinical medicine, Rubella vaccine, Clinical trials

Phase 1/2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of Micron's Microneedle-Based Measles-Rubella Vaccine

Key Points: 
  • Phase 1/2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of Micron's Microneedle-Based Measles-Rubella Vaccine
    ATLANTA, July 13, 2021 /PRNewswire/ - Micron Biomedical, Inc. ("Micron" or the "Company"), a leader in dissolving, microneedle-based vaccine and drug delivery, today announced that it has initiated a Phase 1/2 clinical trial of its microneedle-based measles-rubella ("MR") vaccine.
  • The trial will assess the safety, tolerability and immunogenicity of an MR vaccine delivered using Micron's technology, compared with delivery via standard subcutaneous injection, in adults and children.
  • "This trial reinforces Micron's position as a leader in microneedle-based vaccine and drug delivery technology, and we are excited to be collaborating with Dr. Clarke and the MRCG at LSHTM on this groundbreaking clinical trial."
  • Micron is an Atlanta based company whose microneedle technology was initially developed at Georgia Tech in the lab of Mark Prausnitz, PhD.

InDevR Launches VaxArray Measles and Rubella Kit for Improved Vaccine Antigen Characterization

Retrieved on: 
Tuesday, January 19, 2021
Medical specialties, Clinical medicine, Infectious diseases, Pediatrics, Vaccine-preventable diseases, Vaccination, Virology, Vaccines, Vaccine, Rubella, Measles, Rubella vaccine

BOULDER, Colo., Jan. 19, 2021 /PRNewswire/ --InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and biotherapeutics, announced commercial availability of its VaxArray Measles and Rubella (MR) antigen quantification kit.

Key Points: 
  • BOULDER, Colo., Jan. 19, 2021 /PRNewswire/ --InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and biotherapeutics, announced commercial availability of its VaxArray Measles and Rubella (MR) antigen quantification kit.
  • Erica Dawson, CTO of InDevR, noted "We are excited to expand on our VaxArray portfolio, which currently includes influenza and coronavirus solutions, by adding this measles and rubella kit to streamline vaccine manufacturing processes.
  • We hope the availability of this new tool will help expedite MR bioprocess development and monitoring, thereby enhancing production and reducing the cost per dose of final vaccine."
  • This is a significant improvement compared to the traditional long duration and tedious tissue culture-based methodology."

InDevR Launches VaxArray Measles and Rubella Kit for Improved Vaccine Antigen Characterization

Retrieved on: 
Tuesday, January 19, 2021
Medical specialties, Clinical medicine, Infectious diseases, Pediatrics, Vaccine-preventable diseases, Vaccination, Virology, Vaccines, Vaccine, Rubella, Measles, Rubella vaccine

BOULDER, Colorado, Jan. 19, 2021 /PRNewswire/ --InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and biotherapeutics, announced commercial availability of its VaxArray Measles and Rubella (MR) antigen quantification kit.

Key Points: 
  • BOULDER, Colorado, Jan. 19, 2021 /PRNewswire/ --InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and biotherapeutics, announced commercial availability of its VaxArray Measles and Rubella (MR) antigen quantification kit.
  • Erica Dawson, CTO of InDevR, noted "We are excited to expand on our VaxArray portfolio, which currently includes influenza and coronavirus solutions, by adding this measles and rubella kit to streamline vaccine manufacturing processes.
  • We hope the availability of this new tool will help expedite MR bioprocess development and monitoring, thereby enhancing production and reducing the cost per dose of final vaccine."
  • This is a significant improvement compared to the traditional long duration and tedious tissue culture-based methodology."

WebMD Poll: More than half will get Covid-19 vaccine in first year, 42% in first six months

Retrieved on: 
Wednesday, September 2, 2020
Drugs, RTT, Medical specialties, Vaccination, Vaccines, Vaccine, MMR vaccine, Influenza vaccine, Rubella vaccine, Mumps, HPV vaccine, Vaccination policy

Fewer than one-third say they will get the vaccine in the first three months, which is consistent in both polls.

Key Points: 
  • Fewer than one-third say they will get the vaccine in the first three months, which is consistent in both polls.
  • In the new poll, about 12% said they will not get a vaccine at all, and the rest remain unsure.
  • Vaccine efficacy rates range from about 40% to 60% for the seasonal flu vaccine, to 97% for the measles, mumps and rubella vaccine, according to CDC data .
  • "Understanding how well the vaccine works could be a hurdle for patients," said John Whyte, MD, chief medical officer of WebMD.

COVID-19 and Kawasaki Disease: Low MMR Vaccine Responsiveness Could Be Affecting Children According to World Organization

Retrieved on: 
Thursday, May 14, 2020
Medical specialties, RTT, Medicine, Drugs, Vaccines, Pediatrics, Vaccine-preventable diseases, Rubella, MMR vaccine, Rubella vaccine, Vaccine, Measles

Some young children with a rare condition known as Kawasaki disease are, however, getting severe COVID-19 complications which could relate to a relationship between MMR vaccines and COVID-19.

Key Points: 
  • Some young children with a rare condition known as Kawasaki disease are, however, getting severe COVID-19 complications which could relate to a relationship between MMR vaccines and COVID-19.
  • A tremendous amount of data points to the conclusion that the rubella component of MMR vaccines is what protects most children from COVID-19.
  • The 1999 study by Kuijpers et al Kawasaki Disease: A Maturational Defect in Immune Responsiveness concluded that an incomplete responsiveness to measles-mumps-rubella vaccination was seen in patients with Kawasaki disease.
  • It follows that to the extent MMR vaccines are guarding children from COVID-19, those who have Kawasaki disease could be left largely unprotected.